Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)

Summary

This study is designed to investigate, at first, safety and tolerability of a novel liquid vaccine formulation named MV-ZIKA-RSP, in healthy adults aged 18 to 55 years

Timeline

Start

2019-08-02

Primary completion

2020-01-30

Completion

2020-06-10

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

registry analysis (superiority test); Group A: V187 (High Dose) - V187 (High Dose) vs Group B: V187 (Low Dose) - V187 (Low Dose) vs Group C: V187 (High Dose) - Placebo vs Group D: Placebo - Placebo; p = 0.2003; Fisher-Freeman-Halton Test NCT04033068 ↗

Publications

• Results Rossi SL, Comer JE, Wang E, Azar SR, Lawrence WS, Plante JA, Ramsauer K, Schrauf S, Weaver SC. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates. J Infect Dis. 2019 Jul 31;220(5):735-742. doi: 10.1093/infdis/jiz202.

Drugs

Indications